

HOW TO PRESCRIBE MEDICATIONS IN PATIENTS WITH CHRONIC LIVER DISEASE

Miguel de Varona Negron, M.D. Auxilliary Professor of Medicine Division Of Gastroenterology and Hepatology UPR School of Medicine












Introduction



- Liver is a primary site of drug metabolism
- The liver plays a central role:
 - absorption
 - distribution
 - elimination
- Dose adjustment in patients with liver dysfunction is therefore essential for many drugs



Introduction

- Almost 50% of the drugs are associated with some sort of liver injury
- Nearly 100 drugs are known to cause fulminant hepatic failure
- 10% of all adverse drug reactions are hepatotoxicity
- 30% of cirrhotic patients suffer adverse drug reactions




80% could be prevented

Hepatic Pathophysiology

- Any compound entering the body must eventually be eliminated by:
 - metabolism
 - excretion via the urine or bile/feces
- "First pass effect"
 - Responsible for the pre-systemic elimination
 - Small bowel epithelium
 - Liver









- Alterations in hepatic blood flow
 - decreased portal blood flow
 - increased hepatic arterial resistance
 - capillarization of the hepatic sinusoids


The Permeability of the Hepatic Sinusoid Varies in Health and Disease



- Portosystemic shunting
 - may permit cardioactive substances to bypass the liver
 - prolongation of the QTc interval



- Changes in cytochrome P450 activity
- Hypoalbuminemia
 - impaired production
 - dilution from fluid retention
 - high-binding profile to albumin = more unbound drug in the serum
- Cholestasis



- Cholestasis
 - Impaired bilirubin secretion and bile formation = increase serum drug levels
- Portal hypertension
 - Ascites
 - impact the volume of distribution
 - intestinal edema and impaired permeability



- Portal gastropathy
 - impact absorption of oral medications
 - impact the drug's bioavailability
- Renal blood flow
 - impact renal blood flow
 - decreased renal clearance of medications



Liver Function Assessment

 Patients with well compensated cirrhosis and near normal synthetic function will have a lesser extent of impaired drug metabolism as compared to patients with decompensated cirrhosis, synthetic dysfunction and portal hypertension



Liver Function Assessment

- No evidence-based guidelines exist for the use of medications in patients with liver cirrhosis
- Child-Pugh score and MELD score are used for prediction of impaired liver function



Child-Turcotte-Pugh Score

Clinical and Lab Criteria	Points*				
	1	2	3		
Encephalopathy	None	Mild to moderate (grade 1 or 2)	Severe (grade 3 or 4)		
Ascites	None	Mild to moderate (diuretic responsive)	Severe (diuretic refractory)		
Bilirubin (mg/dL)	< 2	2-3	>3		
Albumin (g/dL)	> 3.5	2.8-3.5	<2.8		
Prothrombin time Seconds prolonged	<4	4-6	>6		
International normalized ratio	<1.7	1.7-2.3	>2.3		

Child-Turcotte-Pugh Class obtained by adding score for each parameter (total points)

Class A = 5 to 6 points (least severe liver disease)

Class B = 7 to 9 points (moderately severe liver disease)

Class C = 10 to 15 points (most severe liver disease)



MELD Score


Model for End Stage Liver Disease (MELD)

MELD score= 10x[0.957x log e (creatinine) + log e (bilirubin) + 1.12 x log e (INR)] + 6.43

3 month mortality according to MELD score

MELD score	<=9	10-19	20-29	30-39	<u>>=40</u>
Hospitalized pt.	4%	27%	76%	83%	100%
Outpatient cirrhotic	2%	6%	50%		

3-Month Patient Mortality






Child-Pugh and MELD Scores

 These classification schemes lack the sensitivity to quantify the specific ability of the liver to metabolize individual drugs





Drug Prescribing



Prescribing Medications



- Drug dosing should be individualized
- Toxicity is accentuated by factors like nutritional status, renal function and drugdrug interactions
- If possible, measure drug level in the blood
- Educate patient to recognize signs of liver injury (nausea, jaundice, abdominal pain)
- Monitoring of the liver function at frequent intervals is highly recommended



ANTIBIOTICS



Antibiotic Dosing in Cirrhosis

- Liver is an important site of removal of blood borne bacteria
- 5 to 7 fold increase in bacteremia due to suppressed immunity
- Frequent use of antibiotics for therapeutic or prophylactic purpose





Antibiotics Dosing in Cirrhosis



- Macrolide antibiotics are excreted and detoxified by the liver and should be used with caution in cirrhotic patients
 - 1. Erythromycin
 - 2. Azithromycin
 - 3. Chloramphenicol
 - <mark>4</mark>. Clindamycin
- * Watch for QTc prolongation





Fluoroquinolones


- Among the most used in cirrhotic patients
 Treat and prevent SBP
- Norfloxacion, ciprofloxacin, levofloxacin
 - No extensive hepatic metabolism
 - Adjustment needed with renal impairment
- Watch for QTc prolongation
 - TIPS patients





TIPS and PS Shunts


- Loss in first pass metabolism of midazolam
 Nifedipine as well
- Baseline QTc interval prolongation
 - SBP prophylaxis
 - Fluoroquinolones





Beta-Lactamic Antibiotics

- This family includes:
 - Penicillin derivatives
 - Cephalosporins
 - Monobactams
 - Carbapenems



- Monitor for beta-lactam associated leukopenia
- Cefepime induced encephalopathy



Metronidazole

- Reduce dose by 50% in patients with severe cirrhosis (Child Class C) or renal insufficiency
- Use bid schedule instead of tid



Antifungals



- Ketoconazole, voriconazole, fluconazole and miconazole though hepatotoxic can be used with caution in patients with cirrhosis
- Monitor drug concentration in serum
- Newer antifungal agents
 - Echinocandins





Antibiotics



- Tetracycline, Isoniazid and Rifampin have prolonged half life in patients with cirrhosis
- Antituberculosis therapy (ATT) is associated with hepatotoxicity in 10%
- ATT in Child Class A cirrhosis is the same as non-cirrhotic population.
- Pyrazinamide should be avoided in Child B-C disease.





Antituberculosis Therapy

- Isoniazid may accumulate in advanced cirrhosis.
- Rifampin is eliminated in bile
 - Bilirubin elevation due to competitive inhibition
 - Hepatotoxicity is increased with Isoniazid



Anti-viral agents

- HIV therapy
- Anti Hepatitis C agents
 - Limitations according to Child score
- Anti Hepatitis B agents
 - Tolerated in decompensated cirrhotic patients



ANESTHETIC AGENTS



Anesthetic Agents

- General anesthesia reduces the hepatic blood flow resulting in decompensation
- Halothane should be avoided
- Isoflurane, desflurane are safe since they are not significantly metabolized by the liver
- Fentanyl and Propofol are good agents for combination anesthesia
- Consider spinal anesthesia





ropoto

ANALGESICS

TYLENOL

-

WANTED BEIDING FOR PARTY

ANACIN

AND I



Analgesics



- Pain management in cirrhosis is a cnallenging task
- Analgesic choice depends on etiology of cirrhosis, renal function, liver transplant candidacy, drug interactions, adherence
- Analgesics are associated with severe complications
 - NSAID's: GI bleeding and renal failure; refractory ascites



Opioids: encephalopathy



Analgesics



- Acetaminophen at a dose <2g/day is a safe option
- Tramadol 25 mg every 8 hours can be used
- Fentanyl topical patch can be used or oral hydromorphone (avoid combinations)
- Neuropathic pain: Gabapentin, pregabalin, nortryptyline and desipramine can be used





ANTICONVULSANTS



ORTHO MENCE NEUROLOGIC



Anticonvulsants



- Phenytoin
 - Generally avoided in cirrhosis
 - Lower plasma concentration needed
 - Avoid in alcoholic patients
- Carbamazepine
 - Avoid in cirrhosis; may induce decompensation.
- Valproate can be hepatotoxic
 - May precipitate encephalopathy



Hyperammonemia



Anticonvulsants

- Levetiracetam (Keppra): safe
 - Adjust if renally impaired
- Topiramate
 - Avoid combination with enzyme inducers
 - Avoid in renal impairment (CrCl<6oml/min)</p>
- Lamotrigine (Lamictal)
 - Reduce 25% dosing if moderate to severe hepatic impairment without ascites.
 - Reduce 50% dosing if moderate to severe hepatic impairment with ascites.



Frequently Prescribed Drugs

Antidepressants and Antacids



Antidepressants



- Selective Serotonin Reuptake Inhibitors
 - Fluvoxamine (Luvox[™])
 - 2. Paroxetine (Paxil[™])
 - 3. Fluoxetine (Prozac[™])
 - Need dose modification in patients with cirrhosis (usually decreased by 50%)

Anti-psychotics

- Haloperidol (Haldol)
 - Avoid with active alcohol consumption
 - Avoid in TIPS or surgical shunts
 - May induce QTc prolongation
- Olanzapine (Zyprexa) and Quetiapine (Seroquel)
 - Need lower doses because they undergo extensive CYP metabolism



Dyspepsia/Reflux/Peptic Ulcer

- Proton Pump Inhibitors
 - Esomeprazole is preferred due to unchanged pharmacokinetics
- H-2 blockers
 - Avoid cimetidine
 - Encephalopathy
 - Famotidine is preferred
- Avoid metoclopramide (Reglan)



Miscellaneous

Methadone

- Generally safe in cirrhotic patients
- Good info in
 HCV/IVDA/cirrhosis
 studies

Buprenorphine

 Watch for QTc prolongation

Cannabis

- Delta-9-THC
 - CB1/CB2 receptors
- Hep C studies (crosssectional) show fibrosis progression
- HepC/HIV studies show no significant increase in fibrosis progression
- Encephalopathy

CARDIOVASCULAR



Cardiovascular



- Patients with nonalcoholic steatosis-related cirrhosis have increased incidence of dyslipidemia, hypertension and coronary artery disease
- Captopril, Amiodarone and Ticlopidine can cause hepatotoxicity and should be used with caution
- Statins appear to be remarkably safe in patients with liver cirrhosis



Angiotensin-Converting Enzyme (ACE) Inhibitors



- Enalapril
 - Changes in biotransformation were not clinically significant
 - Antihypertensive effect or ACE inhibition not affected
- Ramipril
 - Start at 5 mg or lower and titrate in patients with cirrhosis
- Lisinopril



Excreted unchanged in the urine (no dose adjustment needed)

Angiotensin II Receptor Antagonist

- Losartan (Cozaar[™])
 - Bioavailabilty is doubled in patients with hepatic impairment
 - Lower initial doses are therefore recommended
- Irbesartan (Avapro[™])
 - No significant changes in plasma concentration, renal clearance and accumulation index compared to normal volunteers
 - ✓ No adjustments necessary in hepatic insufficency





- Valsartan (Diovan™)
 - In mild to moderate hepatic impairment, a twofold increase in plasma concentration-time curve value was observed when compared to healthy volunteers
 - Use with caution, dose adjustment generally not needed in mild to moderate liver disease



Calcium Channel Blockers

Verapamil, Diltiazem, Nifedipine

- Metabolized by the liver and undergo extensive first pass metabolism
- 50% decrease in clearance leading to a marked increase in half-life
- Lower initial and maintenance doses are recommended

Amlodipine

- Prolonged half-life in cirrhotic patients
- Decrease initial and maintenance dose in half
- Titrate up at 14 days interval
- Lower extremity edema

Beta adrenergic Blockers

Carvedilol (Coreg)

- Extensively metabolized in the liver
- 36% decrease in plasma clearance
- Significant increase in bioavailability observed in cirrhosis
- Reduction in initial dosage in patients with compensated cirrhosis

 Manufacturer recommends not to administer in clinically manifested hepatic impairment




Non-selective Beta Blockers

Nadolol

- Preferred because of a once daily dose
- Propanolol
 - Twice daily dosing
- Labetalol
 - Beta and Alpha blockade
 - Avoided in liver disease
- Nevibolol



Can increase portal pressures



and death

Sympathetic nervous system and RAAS maximally

Gut bacterial translocation and death

stimulated

Alpha-Adrenergic Blockers

Terazosin

- Extensively metabolized by the liver
- 90% bioavailability
- Hepatic impairment prolongs its effect
- Dose should be reduced, use with caution



Vasodilators

Nitroglycerin

- Very rapid and nearly complete hepatic metabolism
- Lower dose recommended in hepatic impairment because bioavailability may increase



Antiplatelets

Clopidogrel

- Dosage adjustment is not required in patients with mild to moderate hepatic impairment
- Caution recommended in patients with severe hepatic disease



Anticoagulants

Xarelto

- Avoid in Child B-C
- Eliquis
 - Avoid in Child C
- Pradaxa
 - Prodrug
 - Not affected by the CYP 450
- Coumadin



Effects on MELD/Child

How to use STATINS in patients with Liver Disease

CRESTOR (10 mp) T

TO MALES

20 mg 90 tablets

MSD

Zocor*

80 mg




Metabolism of Statins

- Fist-pass hepatic metabolism
- Cytochrome P450 system
 - May utilize different isoenzymes
 - Monitor other drug levels metabolized by the same isoenzyme (eg, Phenytoin)
- 10-20 fold increase in levels of statins in *advanced* cirrhosis
 - Patients with cirrhosis typically have low cholesterol levels and do not require these agents



Metabolism of Statins





Statins

- Statins can and should be prescribed for the same indications in people with chronic liver disease as in those without it
- Statin-induced liver injury is uncommon
- Those with active acute liver disease such as acute viral hepatitis or alcoholic hepatitis should not receive it until they have recovered



Statins and CLD

- 20% of the population has elevated enzymes due to fatty liver disease (NAFLD)
- Statins rarely cause fibrosis
- Statins are under-prescribed
- Statins are used after liver transplantation to treat hyperlipidemia safely






Statins Therapy in patients with CLD:

Start Statin at Low Dose Check AST/ALT Levels in 2 weeks AST or ALT two or more AST or ALT near baseline baseline value level or mildly elevated **Continue Statin Therapy** Monitor monthly x 3 months, **Discontinue Statin** Consider trial of another then 4 times year Statin after AST/AST levels return to baseline

Cleveland Clinic Journal of Medicine. Vol. 71, number 1. January 2004

If dose needs to be increased: Check LFT's in 2 weeks, then monthly x 3 months

How about diabetes medications??





Diabetes medications

- Glucophage
 - Very safe but...
 - Careful in alcoholics or renal insufficiency
- Sulfonylureas/Meglitinides
 - Metabolized in the liver and highly protein bound
 - Avoid in severe CLD/renal insufficiency
- Insulins
- Newer agents



SGLT2 inhibitors, DPP4 inhibitors, GLP-1 agonists

Natural/Herbal Medicines

- High risk for hepatotoxicity
- Determine the need
- Assess for drug-drug interactions
 - Search the LiverTox Database from the NIH
 - https://livertox.nlm.nih.gov/
- Careful with "proprietary blends"



COVID 19 PEARLS

- Remdesivir
 - No dose adjustments
 - Monitor liver enzymes while on therapy
- Hydroxychloroquine (Plaquenil)
 - QTc prolongation
- Tocilizumab (Actemra)
- Siltuximab (Sylvant)


- REGEN-COV
 - Safe in cirrhosis
- Dexamethasone
- Ivermectin
- Immunosuppressive agents in OLT

Conclusion

- Liver disease can enhance the risk of adverse reactions of medications
- No test can determine drug dosing in patients with hepatic impairment
- Most drugs can be used safely
- Drug prescribing should be carefully done in patients with severe liver disease (cirrhosis), especially dose with jaundice, ascites or encephalopathy



...THANK YOU!!!!





References

- Amarapurkar DN. Prescribing medications in patients with decompensated liver cirrhosis. *Intl J Hepatology* 2011; doi:10.4061/2011/519526: pp1-5.
- 2. S.I. Sokol, et al, "Cardiovascular drug therapy in patients with hepatic diseases and congestive heart failure," *Journal of Clinical Pharmacology*, vol. 40, no. 1, pp 11-30, 2000
- R.K. Tandon,"Prescribing in patients with liver disease," Medicine Update 2012, vol. 22, pp. 494-497, 2012
- Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. *Eur J Clin Pharmacol* (2008) 64: 1147-1161



Contraindicated in ascites

- (NSAIDs)
 - high risk of developing further sodium retention, hyponatremia, and renal failure (Level A1).
- Drugs that decrease arterial pressure or renal blood flow
 - ACE-inhibitors, angiotensin II antagonists, or a1-adrenergic receptor blockers (Level A1).
- Aminoglycosides
 - reserved for patients with bacterial infections that cannot be treated with other antibiotics (Level A1).
- In patients with ascites without renal failure,
 - the use of contrast media does not appear to be associated with an increased risk of renal impairment (Level B1).
 - Contrast media should be used with caution and the use of general preventive measures of renal impairment is recommended (Level C1).



Types of Drug-Induced Liver Injury

- Indirect
 - caused by the action of the drug (what it does) rather than by its toxic or idiosyncratic properties (what it is)
 - induction of a new liver condition
 - exacerbation of a preexisting condition
 - induction of immune-mediated hepatitis
 - worsening of hepatitis B or C



Drug induced liver injury (DILI)

- The diagnosis is challenging.
 - based largely on exclusion of other causes
- Timing of the onset of injury after the implicated agent has been started (latency)
- Resolution after the agent is stopped (dechallenge)
- Recurrence on re-exposure (rechallenge)
- Knowledge of the agent's potential for hepatotoxicity (likelihood)
- Clinical features (phenotype)



DILI

- There are no specific diagnostic markers for druginduced liver injury
- Special tests
 - liver biopsy, imaging, and testing for serologic markers
 - helpful mostly in ruling out other causes of liver injury



Types of Drug-Induced Liver Injury

- Direct
 - caused by agents that are intrinsically toxic to the liver.
 - is common, predictable, dose-dependent, and reproducible in animal models.




Types of Drug-Induced Liver Injury

- Idiosyncratic
 - caused by agents that have little or no intrinsic toxicity and that cause liver injury only in rare cases
 - is unpredictable, not dose-dependent, and not reproducible in animal models.



Hepatic Pathophysiology

- Drug biotransformation in the liver is dependent on two factors:
 - 1. Hepatic blood flow
 - 2. Metabolic capacity of the liver





In patients with liver cirrhosis, impaired drug handling is due to:

- **1**. Liver cell necrosis
- 2. Shunting of the blood through porto- systemic collaterals
- 3. Reduction in the concentration of drug binding protein
- 4. Abnormal drug volume distribution
- 5. Altered drug elimination
- 6. Altered drug metabolism
- 7. Associated renal failure
- 8. Drug-drug interactions

